Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.57 |
| ▸ | CES2 | O00748 | 2/20 | 0.43 |
| ▸ | CES1 | P23141 | 2/20 | 0.43 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.36 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.36 |
| ▸ | CHRNG | P07510 | 1/20 | 0.36 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.36 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.36 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.36 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.36 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.36 |
| ▸ | CHRND | Q07001 | 1/20 | 0.36 |
| ▸ | GRM5 | P41594 | 1/20 | 0.34 |
| ▸ | GPR139 | Q6DWJ6 | 2/20 | 0.33 |
| ▸ | DGAT2 | Q96PD7 | 2/20 | 0.32 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2958907 | 1.00 | SLC6A3 (0.57) | SLC6A3CES2CES1MAP4K4ALDH1A1 | |
| SCHEMBL2958906 | 1.00 | SLC6A3 (0.57) | SLC6A3CES2CES1MAP4K4ALDH1A1 | |
| SCHEMBL13001617 | 0.83 | SLC6A3 (0.53) | SLC6A3CES2CES1ALDH1A1HPGD | |
| SCHEMBL4394472 | 0.81 | CA12 (0.41) | SLC6A3ALDH1A1CYP2B6 | |
| SCHEMBL4393402 | 0.76 | PGR (0.46) | CES2CES1ALDH1A1HPGDGPR139 | |
| SCHEMBL4394358 | 0.74 | KDM4E (0.57) | SLC6A3CHRNA1CHRNGCHRNB1CHRNB2 | |
| SCHEMBL3305385 | 0.74 | SLC6A3 (0.62) | SLC6A3CES2CES1ALDH1A1HPGD | |
| SCHEMBL1226538 | 0.74 | SLC6A3 (0.62) | SLC6A3CES2CES1ALDH1A1HPGD | |
| SCHEMBL5966780 | 0.73 | MEN1 (0.40) | — | |
| SCHEMBL634113 | 0.72 | SLC6A3 (1.00) | SLC6A3CES2CES1ALDH1A1GRIA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100311727-A1 | THERAPEUTIC AMINE-ARYLSULFONAMIDE CONJUGATE COMPOUNDS | ALGEBRA, INC. (US) | 2010-12-09 | — | — | US | claimed |
| US-7763612-B2 | Therapeutic amine-arylsulfonamide conjugate compounds | ALGEBRA, INC. (US) | 2010-07-27 | — | — | US | claimed |
| US-20070155729-A1 | THERAPEUTIC AMINE-ARYLSULFONAMIDE CONJUGATE COMPOUNDS | ALGEBRA, INC. (US) | 2007-07-05 | — | — | US | claimed |
| US-20100311727-A1 | THERAPEUTIC AMINE-ARYLSULFONAMIDE CONJUGATE COMPOUNDS | ALGEBRA, INC. (US) | 2010-12-09 | — | — | US | disclosed |
| US-7763612-B2 | Therapeutic amine-arylsulfonamide conjugate compounds | ALGEBRA, INC. (US) | 2010-07-27 | — | — | US | disclosed |
| US-20070155729-A1 | THERAPEUTIC AMINE-ARYLSULFONAMIDE CONJUGATE COMPOUNDS | ALGEBRA, INC. (US) | 2007-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070155729-A1 | THERAPEUTIC AMINE-ARYLSULFONAMIDE CONJUGATE COMPOUNDS | AADAT, AADAC, AANAT | SLC6A3 21/4885CES2 246/4885CES1 820/4885 |
| US-20100311727-A1 | THERAPEUTIC AMINE-ARYLSULFONAMIDE CONJUGATE COMPOUNDS | AADAT, AADAC, AANAT | SLC6A3 21/4885CES2 246/4885CES1 820/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.